OTCMKTS:EMMA Emmaus Life Sciences (EMMA) Stock Price, News & Analysis $0.01 0.00 (-9.17%) As of 08/29/2025 02:25 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Emmaus Life Sciences Stock (OTCMKTS:EMMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Emmaus Life Sciences alerts:Sign Up Key Stats Today's Range$0.0109▼$0.011050-Day Range$0.0109▼$0.016052-Week Range$0.00▼$0.05Volume323,580 shsAverage Volume29,742 shsMarket Capitalization$696.18 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California. Read More Receive EMMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EMMA Stock News HeadlinesEmmaus Life Sciences Reports Quarterly Financial ResultsAugust 14, 2025 | prnewswire.comEmmaus Life Sciences Inc. Annual Income Statement - MarketWatchJuly 9, 2025 | marketwatch.comThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”August 31 at 2:00 AM | Weiss Ratings (Ad)Emmaus Life Sciences, Inc.: Emmaus Life Sciences Receives FDA Approval for Endari Label Enhancements - FinanzNachrichten.deJune 28, 2025 | finanznachrichten.deEmmaus Life Sciences Receives FDA Approval for Endari® Label EnhancementsJune 26, 2025 | prnewswire.comEmmaus Life Sciences Reports Quarterly Financial ResultsMay 15, 2025 | prnewswire.comEmmaus Life Sciences IncApril 18, 2025 | uk.investing.comEmmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi ArabiaJanuary 29, 2025 | finance.yahoo.comSee More Headlines EMMA Stock Analysis - Frequently Asked Questions How have EMMA shares performed this year? Emmaus Life Sciences' stock was trading at $0.0085 at the start of the year. Since then, EMMA stock has increased by 28.2% and is now trading at $0.0109. How were Emmaus Life Sciences' earnings last quarter? Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) released its earnings results on Thursday, August, 14th. The company reported ($0.02) EPS for the quarter. The firm had revenue of $2.82 million for the quarter. How do I buy shares of Emmaus Life Sciences? Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Emmaus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emmaus Life Sciences investors own include Humanigen (HGEN), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Acasti Pharma (ACST), Actinium Pharmaceuticals (ATNM) and Entasis Therapeutics (ETTX). Company Calendar Last Earnings8/14/2025Today8/31/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:EMMA CIK822370 Webwww.emmausmedical.com Phone(310) 214-0065Fax866-294-2611Employees60Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.45 million Net Margins-24.20% Pretax Margin-28.35% Return on EquityN/A Return on Assets-14.00% Debt Debt-to-Equity RatioN/A Current Ratio0.08 Quick Ratio0.06 Sales & Book Value Annual Sales$16.65 million Price / Sales0.04 Cash FlowN/A Price / Cash FlowN/A Book Value($0.87) per share Price / Book-0.01Miscellaneous Outstanding Shares63,870,000Free Float41,513,000Market Cap$696.18 thousand OptionableNot Optionable Beta8.03 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:EMMA) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emmaus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emmaus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.